Any current/future new fundraising through debt or equity?

KIMS Hospitals plans to fund growth primarily through internal accruals and debt while maintaining a debt-equity ratio within 0.75:1 and debt-to-EBITDA below 1.75:1. The company may slightly exceed their capex and EBITDA limits in the next 2-3 quarters but plans to stabilize thereafter. For expansion opportunities, they consider two options: raising funds via an IPO or taking on some debt leverage. Current average cost of borrowing is about 8.5%, and they expect this to continue in the near term. No immediate plans for a large-scale equity raise; focus is on using internal resources complement

Any current/future capex/capital investment/strategic investment?

Construction of a new tower replacing demolished Block 1 and Block 2 at Secunderabad, accommodating 350-400 incremental beds; capex incurred over time as required (Page 18). Vizag unit acquisition with potential for scale-up; capital costs to be managed via internal accruals and controlled debt (Page 20, 7). Capex planned for upgrading acquired cancer facility (~INR 20-25 crores for renovations) without major medical equipment spend for 2-3 years (Page 8). New hospital cluster development in Karnataka (Sarjapura land parcel) planned post stabilization of currently acquired hospitals; equity in

Future growth expectations in sales/revenue/volumes?

Expansion plans include adding 350-400 beds via new towers and new hospitals in Thane, Nashik, Bengaluru, and Vizag. Vizag hospital acquisition currently generates around INR 65-70 crores revenue, with potential to scale back to INR 120-150 crores. IP volumes show consistent growth (7.5% YoY), with ongoing efforts to optimize Operational Metrics like Average Length of Stay (ALOS). Existing hospitals expected to sustain growth, with incremental contributions from newly acquired or commissioned hospitals like Queen’s NRI and Nashik. Occupancy targets of 65-70% over next 3-4 years expected to dri

Future growth expectations in earnings/operating earnings/profits/EPS?

Growth in absolute bottom-line numbers is expected to continue despite some percentage fluctuations during new unit ramp-up phases. Andhra cluster EBITDA margins could rise from current mid-20% range to around 27-28% over the next 24-36 months as units mature. Telangana units are mature with stable margins; incremental revenue is expected to flow through at 35-40% to EBITDA. New hospitals like Nashik and Queen's NRI are expected to contribute positively after initial first-half drag. Average Revenue Per Operating Bed (ARPOB) is expected to sustain in the 36,000-38,000 range. PAT grow

Krishna Institu.Q1 FY25Healthcare Services

Krishna Institu. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹736P/E: 157.1Market Cap: ₹32.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Expansion plans include adding 350-400 beds via new towers and new hospitals in Thane, Nashik, Bengaluru, and Vizag.
Vizag hospital acquisition currently generates around INR 65-70 crores revenue, with potential to scale back to INR 120-150 crores.
IP volumes show consistent growth (7.5% YoY), with ongoing efforts to optimize Operational Metrics like Average Length of Stay (ALOS).
Existing hospitals expected to sustain growth, with incremental contributions from newly acquired or commissioned hospitals like Queen’s NRI and Nashik.
Occupancy targets of 65-70% over next 3-4 years expected to drive volume growth.
Insurance penetration growth is significant in metro and Tier 1 cities but slower in Tier 2 and 3.
EBITDA margin growth expected with revenue scale-up and new specialties added.
Capital constraints may limit bed capacity expansion unless leverage or funding (IPO/debt) raised.

Margin guidance

Category 3

Growth in absolute bottom-line numbers is expected to continue despite some percentage fluctuations during new unit ramp-up phases.
Andhra cluster EBITDA margins could rise from current mid-20% range to around 27-28% over the next 24-36 months as units mature.
Telangana units are mature with stable margins; incremental revenue is expected to flow through at 35-40% to EBITDA.
New hospitals like Nashik and Queen's NRI are expected to contribute positively after initial first-half drag.
Average Revenue Per Operating Bed (ARPOB) is expected to sustain in the 36,000-38,000 range.
PAT growth recorded +7% YoY and +32% QoQ in Q1 FY25 with EPS growing similarly; this momentum is anticipated to sustain.
Capex-funded expansions to be cautiously managed leveraging internal accruals and limited debt (debt/equity capped at 0.75:1), implying sustainable growth.
Management prefers internal accruals and moderate debt for growth over fresh IPOs.

See what Krishna Institu. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

KIMS Hospitals plans to fund growth primarily through internal accruals and debt while maintaining a debt-equity ratio within 0.75:1 and debt-to-EBITDA below 1.75:1.
The company may slightly exceed their capex and EBITDA limits in the next 2-3 quarters but plans to stabilize thereafter.
For expansion opportunities, they consider two options: raising funds via an IPO or taking on some debt leverage.
Current average cost of borrowing is about 8.5%, and they expect this to continue in the near term.
No immediate plans for a large-scale equity raise; focus is on using internal resources complemented by manageable debt to fund ongoing and future expansions.
Debt is expected to increase from around INR1,150 crores as of June 2024 to INR1,600-1,700 crores by year-end due to new hospital commissions.

Order book

The transcript does not explicitly mention any current or expected order book or pending orders for KIMS Hospitals. However, related insights regarding growth, expansion, and capex include: - Ongoing expansion with new hospitals coming up in Nashik, Thane, Bengaluru, and Vizag. - Demolition and rebuilding of new towers to add 350-400 beds, with operationalization as needed. - Vizag unit acquisition valued around INR65-70 crores revenue currently, with potential for scale-up. - Planned capex largely funded through internal accruals and limited debt, maintaining debt-to-equity within 0.75-1. - No specific mention of order book or pending orders from customers or government contracts. - Focus on channelizing capex based on opportunities from existing and new units. - Potential IPO or additional leveraging for expansions if needed. No explicit "order book" data is provided.

See what Krishna Institu. management said on order book — free account, 30 seconds.

Capex plans

Yes

Construction of a new tower replacing demolished Block 1 and Block 2 at Secunderabad, accommodating 350-400 incremental beds; capex incurred over time as required (Page 18).
Vizag unit acquisition with potential for scale-up; capital costs to be managed via internal accruals and controlled debt (Page 20, 7).
Capex planned for upgrading acquired cancer facility (~INR 20-25 crores for renovations) without major medical equipment spend for 2-3 years (Page 8).
New hospital cluster development in Karnataka (Sarjapura land parcel) planned post stabilization of currently acquired hospitals; equity infusion from partners (Page 12).
Upcoming hospital launches in Nashik, Thane, and Bengaluru on track; Nashik operationalizing 75-80 beds, capex partially incurred or ongoing (Page 6, 7, 16).
Capex and EBITDA cautiously managed; possibility to cross existing limits temporarily in 2-3 quarters to seize growth opportunities, with options for IPO or limited debt leverage if needed (Page 20).
Capital constraint is a primary limit; company aims to keep debt-equity at 0.75:1 and debt-to-EBITDA at 1.75:1 (Page 16).

Track Krishna Institu. — get its next earnings analysis in your feed

How does Krishna Institu. rank vs peers in Healthcare Services?

Pro feature

ThisKrishna Institu.

Rev 3Mar 3

See where Krishna Institu. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Krishna Institu. rank in Healthcare Services?

Compare Krishna Institu. against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Krishna Institu.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Krishna Institu. Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Krishna Institu. rank in Healthcare Services?

Continue your research

What Krishna Institu.'s management said in earlier quarters

Others in Healthcare Services this season